Loading
institutionsInstitution
Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine
Baylor's Duncan Comprehensive Cancer Center sits in Houston's Texas Medical Center; its Center for Cell and Gene Therapy pioneered virus-specific T cells and ran the first GD2 CAR-T trial in neuroblastoma in 2008, and its genome centre sequenced tumours for The Cancer Genome Atlas.
Also called: Duncan Cancer Center
Overview
NCI-designated in 2007 and comprehensive since 2015, the Duncan Comprehensive Cancer Center sits beside MD Anderson in Houston's Texas Medical Center and works through Baylor St. Luke's, Texas Children's and the Michael E. DeBakey VA hospitals. Its Center for Cell and Gene Therapy (Malcolm Brenner, Helen Heslop, Cliona Rooney) pioneered virus-specific T cells, multi-antigen T cells and, in 2008, the first GD2 CAR-T trial in neuroblastoma; it spun out several cell therapy companies. The Human Genome Sequencing Center under Richard Gibbs sequenced tumours for The Cancer Genome Atlas, and the Lester and Sue Smith Breast Center (Kent Osborne, Matthew Ellis, Rachel Schiff) is a leader in endocrine resistance.
Location
Houston, TX, US
Type
cancer center · Baylor College of Medicine
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
NCI designation
comprehensive
OnCo score
#89 · 41 points (0 Newsweek + 15 NCI + 26 from 13 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-24.
Matched to Baylor College of Medicine, including child institutions. 1,495 works · 18,767 citations · 67% open access · 9% clinical trials · 2% reviews.
Oncology works per year
3082022
3712023
3242024
2772025
2152026
Most works
- Helen Elisabeth Heslop51 works
- Maksim Mamonkin44 works
- Malcolm K. Brenner37 works
- Alastair Mark Thompson35 works
- Mothaffar F. Rimawi31 works
- LaQuisa Chimere Hill30 works
- Yinghong Wang29 works
- Rayne Helen Rouce27 works
- Cliona M. Rooney27 works
- Premal Lulla27 works
Most cited
- Cell and gene therapy
- Cancer genomics (HGSC)
- Breast cancer endocrine resistance
Similar pages
- IdeaGD2 CAR-T as consolidation in high-risk neuroblastoma
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric), CAR-T cell therapy.
- PersonMichael D. Taylor
Shares Texas Children's Cancer and Hematology Center, Whole-exome & whole-genome sequencing.
- PersonCrystal L. Mackall
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric), CAR-T cell therapy.
- CompanyCaribou Biosciences
Shares Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- TrialGD2-CART01 (Bambino Gesù phase 1/2)
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric), CAR-T cell therapy.
- IdeaOpen the barrier so engineered immune cells can enter the brain
Shares GD2 (disialoganglioside), Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- PersonPolina Stepensky
Shares Allogeneic (off-the-shelf) cell therapy, Manufacturing cost and time for living and radioactive medicines, CAR-T cell therapy.
- PairingAnti-GD2 antibody + irinotecan-temozolomide (chemoimmunotherapy)
Shares GD2 (disialoganglioside), Neuroblastoma (paediatric).